Safer prescribing · MICA
Identify profiles where alternatives need consideration.
Sources consulted 16 October 2026 · MICA scientific review to be confirmed
EMA advises use only without suitable alternatives in people aged 65 or over, those at increased cardiovascular or cancer risk, and current or past long-term smokers. [1]
Reassess thromboembolic risk, infections and skin findings; follow the individual product information. [1]
These measures concern JAK inhibitors for chronic inflammatory disease; they do not make indications or doses interchangeable. [1]
Personal reading prompts; no clinical data is recorded.
FICTIONAL LEARNING SCENARIO
Does age alone determine a universal dose?
No. Check the drug, indication and SmPC. [1]
Non-exhaustive adult learning guidance. Check indication, contraindications, product information and local context before an individual decision. Cited recommendations do not establish marketing authorisation in Algeria.